科兴制药2025年净利润大增406.47% 海外收入实现强劲增长

Core Viewpoint - The company reported significant growth in its 2025 performance, driven by strong overseas market expansion and successful product launches [2] Financial Performance - In 2025, the company achieved total revenue of 1.541 billion yuan, representing a year-on-year increase of 9.54% [2] - The net profit attributable to the parent company reached 159 million yuan, a substantial increase of 406.47% compared to 31.48 million yuan in the same period of 2024 [2] Market Expansion - The company's overseas revenue saw significant growth, contributing to the overall increase in revenue and profit [2] - The company has established a global market presence in approximately 70 countries and regions, including the EU, Brazil, the Philippines, and Indonesia [2] - The company's core product, albumin paclitaxel, was approved for sale in the EU in 2024, with export volume in the first half of 2025 accounting for 47.7% of China's total exports of similar products [2] Innovation and R&D - The company's long-term commitment to innovation and R&D has entered a phase of成果转化 (results transformation), contributing to its explosive growth [2] - The company focuses on three potential areas: oncology, autoimmune diseases, and metabolic diseases, advancing a differentiated pipeline [2] - Several products with "first-in-class" (FIC) or "best-in-class" (BIC) potential have entered critical clinical stages, injecting new momentum for long-term value growth [2]